BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 24729398)

  • 1. Safety and efficacy of golimumab in Chinese patients with active ankylosing spondylitis: 1-year results of a multicentre, randomized, double-blind, placebo-controlled phase III trial.
    Bao C; Huang F; Khan MA; Fei K; Wu Z; Han C; Hsia EC
    Rheumatology (Oxford); 2014 Sep; 53(9):1654-63. PubMed ID: 24729398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Efficacy of Golimumab Administered Intravenously in Adults with Ankylosing Spondylitis: Results through Week 28 of the GO-ALIVE Study.
    Deodhar A; Reveille JD; Harrison DD; Kim L; Lo KH; Leu JH; Hsia EC
    J Rheumatol; 2018 Mar; 45(3):341-348. PubMed ID: 29247154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The safety and efficacy of golimumab in treatment of 25 patients with active ankylosing spondylitis].
    Ma H; Sun F; Zhang YM; Zhang H; Zhu J; Deng XH; Zhang JL; Huang F
    Zhonghua Nei Ke Za Zhi; 2017 Dec; 56(12):935-939. PubMed ID: 29202535
    [No Abstract]   [Full Text] [Related]  

  • 4. Safety and Efficacy of Intravenous Golimumab in Adults with Ankylosing Spondylitis: Results through 1 Year of the GO-ALIVE Study.
    Reveille JD; Deodhar A; Caldron PH; Dudek A; Harrison DD; Kim L; Lo KH; Leu JH; Hsia EC
    J Rheumatol; 2019 Oct; 46(10):1277-1283. PubMed ID: 30824635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study.
    Deodhar A; Braun J; Inman RD; van der Heijde D; Zhou Y; Xu S; Han C; Hsu B
    Ann Rheum Dis; 2015 Apr; 74(4):757-61. PubMed ID: 25387477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis.
    Sieper J; van der Heijde D; Dougados M; Maksymowych WP; Scott BB; Boice JA; Berd Y; Bergman G; Curtis S; Tzontcheva A; Huyck S; Weng HH
    Arthritis Rheumatol; 2015 Oct; 67(10):2702-12. PubMed ID: 26139307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety results from a Phase 3, randomized, placebo-controlled trial of subcutaneous golimumab in Chinese patients with active rheumatoid arthritis despite methotrexate therapy.
    Li Z; Zhang F; Kay J; Fei K; Han C; Zhuang Y; Wu Z; Hsia EC
    Int J Rheum Dis; 2016 Nov; 19(11):1143-1156. PubMed ID: 26259617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of golimumab therapy on disease activity and health-related quality of life in patients with ankylosing spondylitis: 2-year results of the GO-RAISE trial.
    van der Heijde D; Deodhar A; Braun J; Mack M; Hsu B; Gathany TA; Inman RD; Han C;
    J Rheumatol; 2014 Jun; 41(6):1095-103. PubMed ID: 24737912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial.
    Inman RD; Davis JC; Heijde Dv; Diekman L; Sieper J; Kim SI; Mack M; Han J; Visvanathan S; Xu Z; Hsu B; Beutler A; Braun J
    Arthritis Rheum; 2008 Nov; 58(11):3402-12. PubMed ID: 18975305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of golimumab on subclinical atherosclerosis and arterial stiffness in ankylosing spondylitis—a randomized, placebo-controlled pilot trial.
    Tam LS; Shang Q; Kun EW; Lee KL; Yip ML; Li M; Li TK; Zhu TY; Pui MO; Li EK; Yu CM
    Rheumatology (Oxford); 2014 Jun; 53(6):1065-74. PubMed ID: 24501241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.
    Smolen JS; Kay J; Doyle MK; Landewé R; Matteson EL; Wollenhaupt J; Gaylis N; Murphy FT; Neal JS; Zhou Y; Visvanathan S; Hsia EC; Rahman MU;
    Lancet; 2009 Jul; 374(9685):210-21. PubMed ID: 19560810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3.
    Pavelka K; Kivitz A; Dokoupilova E; Blanco R; Maradiaga M; Tahir H; Pricop L; Andersson M; Readie A; Porter B
    Arthritis Res Ther; 2017 Dec; 19(1):285. PubMed ID: 29273067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of adalimumab in Chinese adults with active ankylosing spondylitis: results of a randomised, controlled trial.
    Huang F; Gu J; Zhu P; Bao C; Xu J; Xu H; Wu H; Wang G; Shi Q; Andhivarothai N; Anderson J; Pangan AL
    Ann Rheum Dis; 2014 Mar; 73(3):587-94. PubMed ID: 23475983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT).
    van der Heijde D; Dijkmans B; Geusens P; Sieper J; DeWoody K; Williamson P; Braun J;
    Arthritis Rheum; 2005 Feb; 52(2):582-91. PubMed ID: 15692973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of three enthesitis indices in a multicentre, randomized, placebo-controlled trial of golimumab in ankylosing spondylitis (GO-RAISE).
    van der Heijde D; Braun J; Deodhar A; Inman RD; Xu S; Mack ME; Hsu B
    Rheumatology (Oxford); 2013 Feb; 52(2):321-5. PubMed ID: 23024015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of three methods for calculating the Bath Ankylosing Spondylitis Metrology Index in a randomized placebo-controlled study.
    van der Heijde D; Deodhar A; Inman RD; Braun J; Hsu B; Mack M
    Arthritis Care Res (Hoboken); 2012 Dec; 64(12):1919-22. PubMed ID: 22740380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial.
    van der Heijde D; Kivitz A; Schiff MH; Sieper J; Dijkmans BA; Braun J; Dougados M; Reveille JD; Wong RL; Kupper H; Davis JC;
    Arthritis Rheum; 2006 Jul; 54(7):2136-46. PubMed ID: 16802350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study.
    Braun J; Deodhar A; Inman RD; van der Heijde D; Mack M; Xu S; Hsu B
    Ann Rheum Dis; 2012 May; 71(5):661-7. PubMed ID: 22012970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial.
    Kavanaugh A; van der Heijde D; McInnes IB; Mease P; Krueger GG; Gladman DD; Gómez-Reino J; Papp K; Baratelle A; Xu W; Mudivarthy S; Mack M; Rahman MU; Xu Z; Zrubek J; Beutler A
    Arthritis Rheum; 2012 Aug; 64(8):2504-17. PubMed ID: 22378566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kunxian capsules in the treatment of patients with ankylosing spondylitis: a randomized placebo-controlled clinical trial.
    Li Q; Li L; Bi L; Xiao C; Lin Z; Cao S; Liao Z; Gu J
    Trials; 2016 Jul; 17(1):337. PubMed ID: 27449221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.